Skip to main content

Table 1 (abstract P40). Efficacy in pts with pcJIA at W44

From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)

 

Tofacitinib

PBO

Tofacitinib

PBO

Rate, %

+MTX

N=52

-MTX

N=20

+MTX

N=54

-MTX

N=16

Prior bDMARDs

N=23

No prior bDMARDs

N=49

Prior bDMARDs

N=20

No prior bDMARDs

N=50

JIA flare

28.9

30.0

48.2

68.8

26.1

30.6

70.0

46.0

JIA/ACR50a

65.4

70.0

51.9

31.3

73.9

63.3

30.0

54.0

JIA/ACR70a

53.9

55.0

40.7

25.0

47.8

57.1

25.0

42.0

JIA/ACR90a

36.5

30.0

24.1

12.5

26.1

38.8

10.0

26.0

JIA/ACR-ID

25.0

30.0

18.5

12.5

17.4

30.6

5.0

22.0

∆JADAS27-CRP, LSM (N)

0.9 (36)

-2.4 (13)

3.6 (27)

2.3 (5)

-1.1 (16)

0.8 (33)

12.1 (6)

4.4 (26)

  1. aRelative to study Day 1